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Aberrant Ras signaling drives numerous cancers, and drugs to
inhibit this are urgently required. This compelling clinical need
combined with recent innovations in drug discovery including
the advent of biologic therapeutic agents, has propelledRas back
to the forefront of targeting efforts. Activated Ras has proved
extremely difficult to target directly, and the focus hasmoved to
themain downstreamRas-signaling pathways. In particular, the
Ras-Raf and Ras-PI3K pathways have provided conspicuous
enzyme therapeutic targets that were more accessible to con-
ventional drug-discovery strategies. The Ras-RalGEF-Ral path-
way is amore difficult challenge for traditionalmedicinal devel-
opment, and there have, therefore, been few inhibitors reported
that disrupt this axis.We have used our structure of a Ral-effec-
tor complex as a basis for the design and characterization of
-helical-stapled peptides that bind selectively to active, GTP-
bound Ral proteins and that compete with downstream effector
proteins. The peptides have been thoroughly characterized bio-
physically. Crucially, the lead peptide enters cells and is biolog-
ically active, inhibiting isoform-specific RalB-driven cellular
processes. This, therefore, provides a starting point for thera-
peutic inhibition of the Ras-RalGEF-Ral pathway.
Ras is well established as the most frequently mutated onco-
gene in human cancer. This small G protein cycles between an
active GTP-bound state and an inactive GDP-bound state.
Molecular switching between the “on” and “off” states is posi-
tively regulated by nucleotide guanine exchange factors
(GEFs)4 and negatively regulated by GTPase-activating pro-
teins (GAPs). It is only the active, GTP-bound form of the
protein that can bind to downstream effectors and facilitate
signal transduction.Mutations in oncogenic Ras result in a con-
stitutively active protein that remains fixed in the GTP-bound
on-state, leading to unregulated activation of downstream
pathways. These mutations are found in 30% of all cancers,
with a higher occurrence in specific cancer types such as pan-
creatic (71%) and colorectal (45%) (1). This makes Ras a crucial
cancer therapeutic target; nevertheless, Ras has so far evaded
direct attempts at inhibition, and many Ras-driven cancers are
currently deemed undruggable. Ras signaling has proven diffi-
cult to disrupt by small, drug-like molecules because its activa-
tion of downstream cascades is accomplished through protein-
protein interactions, which have traditionally been avoided as
drug targets due to the large, shallow surfaces involved in pro-
tein-protein interfaces (2–4). Likewise, there are no obvious
clefts or small molecule binding pockets on Ras, and competi-
tive inhibition with the nucleotide is unfeasible due to the
extremely high affinity of GTP binding and its high concentra-
tion in the cellular environment (5, 6). Logical attempts to
interfere with critical post-translational modifications of Ras,
such as inhibition of farnesyltransferase, have also proved
unsuccessful (for reviews, see Refs. 1, 6 and 7). More encourag-
ingly, a specific Ras variant found in lung cancer, G12C, was
successfully used in a recent disulfide fragment-based screen to
identify small molecules that covalently modify this precise Ras
mutant (8). This led to the identification of a potential allosteric
site that may be targetable in this particular mutant. The prob-
lems with attacking Ras directly have driven a broader search
for drug targets that will interfere with Ras signaling, with a
focus on the effector proteins downstream of Ras (for reviews,
see Refs. 1 and 6). After Ras activation there are several path-
ways that propagate the cellular signal, of which at least five
have been implicated in oncogenic signaling (9). Of these, the
Raf, phosphoinositide 3-kinase (PI3K), and RalGEF are the best
validated (6). Both Raf and PI3K have been the object of several
drug discovery initiatives in recent years, with inhibitors of both
proteins currently in clinical trials (10, 11). However, the third
pathway, via RalGEFs, has been less extensively studied, and no
therapies exist that disrupt this signaling route. Despite this, RalA
and RalB have been shown to be important drivers of cell growth,
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cell survival, and metastasis in many human cancers, including
bladder, melanoma, colorectal, and pancreatic (12, 13).
RalGEFs act to activate RalA and RalB, themselves small
GTPases of the Ras superfamily. Like Ras, the Ral proteins cycle
between GTP and GDP-dependent on and off states and are
involved in regulating diverse cellular processes including pro-
liferation, motility, and maintenance of cellular architecture
(13). RalA and RalB are 206 amino acid proteins that are 82%
identical, with 100% identity in the nucleotide-sensitive switch
regions (switch 1 and switch 2). Intriguingly both GTP-loaded
proteins interact directly with the same set of downstream
effectors in vitro, including RLIP76 (or RalBP1), the exocyst
complex subunits Sec5 and Exo84, and the transcription factor
ZO-1-associated nucleic acid-binding protein (ZONAB) (12).
Despite engaging the same collection of effector proteins, RalA
and RalB nevertheless regulate distinct cellular functions and
play different roles in tumorigenesis. This is partly attributable
to the ability of the effectors themselves to promote multiple
signaling pathways. For example, both Ral isoforms interact
with Sec5, which can act as an integral member of the exocyst
complex, controlling exocytosis (14, 15), but RalB-Sec5 can also
engage and activate TBK1 and contribute to cancer cell survival
(16). Interestingly, although RalA and RalB have similar affini-
ties for the effectors that have been tested in vitro (17–19), they
may actually possess different affinities in vivo (20), explaining
some of their distinct cellular functions. Some differences
between RalA and RalB will be due to the hypervariable C-ter-
minal region of the proteins, which is differentially phosphorylated
(21–23) andubiquitinated (24), resulting indistinctive andspecific
subcellular localization for the twoproteins.Differential activation
and deactivation by the RalGEF and RalGAP familymay also con-
tribute to differential roles for the two Ral isoforms. However, no
GEFs have been found that discriminate between the two Ral iso-
forms, and the one structure of a RalGEF with Ral shows that all
the contacts with the GEF protein are conserved between RalA
and RalB (25). Similarly, RalGAPs appear to act on both isoforms
in vitro (26) and in cell lines (27).
Several studies have been reported that attempt to delineate
separate cellular roles for RalA and RalB. siRNA inhibition
experiments showed that knockdown of RalB in HeLa, MCF7,
and SW480 cell lines resulted in apoptosis, with no effect
observed in non-cancerous human cell lines, suggesting that
tumor cells may become dependent on RalB survival pathways
(28). Inhibition of RalA in these experiments had no effect on
adherent cells but impaired anchorage-independent prolifera-
tion of cells in suspension. In contrast, Lim et al. (29) found that
RalA, but not RalB, was required for oncogenic transformation
of human fibroblasts and HEK-HT cells and is critical for Ras-
driven tumorigenesis. Similar effects have been observed in
human pancreatic cancer and colorectal cancer cell lines, and
interestingly, RalB appears to be important during cell invasion
andmetastasis of these cancers (30, 31). The molecular basis of
the divergent functions of RalA and RalB in both normal and
malignant cells remains to be elucidated. It is clear, however,
that both proteins play key roles in tumorigenesis and cancer
progression and are, therefore, potential therapeutic targets.
The Ral proteins adopt the same overall structural fold as Ras
and are, therefore, equally difficult to disrupt using small mol-
ecules. Small molecules that bind to inactive, GDP-bound
forms of Ral have, however, recently been identified using in
silico screens (32). Our solution structure of RalBGMPPNP in
complex with the Ral binding domain of RLIP76 (RLIP76 RBD)
(33) showed novel features for a Ras family-effector complex
and presented an avenue for structure-guided design of inhib-
itors that would target the active, GTP-bound form of the Ral
proteins. The GTP-bound form is generated downstream of
activated Ras, so such inhibitors would bind specifically to
chronically activated Ral, as would be encountered in the dis-
ease context. The structures that are currently available reveal
that most Ras and Ral effectors form intermolecular -sheets
with the small G protein or interact through loops and unstruc-
tured regions (34). In stark contrast, the RLIP76 RBD adopts a
well structured coiled-coil domain consisting of two -helices
that do not significantly change conformation on Ral complex
formation (33). Mimicry of these helices offers an ideal oppor-
tunity to simulate effector binding and inhibit Ral-effector
interactions, stopping signaling from Ral proteins and ulti-
mately from Ras. Biological validation of this proposition has
already been reportedwith the observation that overexpression
of the RLIP76 RBD can interfere with Ral signaling, leading to
mislocalization of Ral-interacting proteins and prevention of
RalA-dependent anchorage-independent growth (14, 28, 35).
In a timely confluence, the mimicry and stabilization of -heli-
ces has been an emerging area in inhibitor design in recent
years, particularly through the use of chemically “stapled” pep-
tides. The introduction of a staple confers multiple, advanta-
geous, drug-like qualities on the peptides; the staple stabilizes
the -helical conformation of small peptides leading to an
increase in binding affinity, it improves the cell penetrating
ability of the peptide, and it enhances the resistance of the pep-
tide to protease degradation. This technique has been success-
fully applied to several different protein targets (36, 37), and the
first stapled peptide-based therapy, a long acting growth hormone
releasing hormone (GHRH) agonist, has passed Phase I clinical
trials, whereas the first anti-cancer stapled peptide, targeting the
reactivation of p53, has also now entered Phase I trials.5 Peptides
based on ahelix from theRas exchange factor SOShave beenused
to target Ras (39, 40), suggesting that small G proteins are amena-
ble to such approaches. The Ras-binding peptides designed so far
are not selective for the GTP-bound form of the Ras protein,
although the stapled versions bind with a high affinity to wild-
type K-Ras and several oncogenic mutants (40).
Here, we report the design and characterization of peptides
based on a single helix of the RLIP76 RBD that bind selectively
to active, GTP-boundRal. Thiswork provides proof of the prin-
ciple that a single helix of RLIP76 is responsible for themajority
of the RLIP76 interactions with Ral and that it is possible to use
this approach to obtain peptides specific to the active form of a
small GTPase.We describe stapled peptides based on this helix
that have cell-penetrating ability and are biologically active.
5 Aileron Therapeutics (2013) Aileron therapeutics initiates phase 1 cancer
study of ALRN-6924 in advanced hematologic and solidmalignancieswith
wild type p53. This trial successfully completed stapled peptide Phase 1
clinical trials (February 12, 2015).
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These peptides provide the basis for furthermaturation to ther-
apeutically useful antagonists of Ral and Ras signaling.
Results
A Peptide Based on RLIP76 RBD 2 Is Sufficient to Bind RalA
and RalB—Our previously reported NMR solution structure of
the RBD of RLIP76 bound to active, GMPPNP-loaded, RalB
(33) showed that RLIP76 employs a coiled-coil motif to bind to
Ral. The structure suggested that most of the key interactions
with Ral are mediated by the C-terminal helix (hereafter 2) of
the RLIP76 RBD coiled-coil (Fig. 1A). Indeed, 80% of the buried
surface area in the complex involves helix2, and alanine-scan-
ning mutagenesis identified more energetic hotspots within
this helix than in 1 (the N-terminal helix of the coiled-coil)
(17). To determine whether helix 2 is sufficient for binding to
RalB, we synthesized two separate peptides based on the con-
tact surfaces in helix 1 and 2. Peptide 1 comprised the full
helix 2 sequence, residues 423–446, to encompass all of the
RalB-interacting residues in this helix. Peptide 2 incorporated
residues 408–422 and comprises residues corresponding to the
last two turns of helix 1 together with the short loop that
connects 1 and 2. This peptide, therefore, includes all the
contacts to RalB outside helix 2.
Circular dichroism (CD) spectroscopy experiments per-
formed on the complete RLIP76 RBD resulted in a characteris-
tic-helical spectrumwithminima at 208 and 222 nm (Fig. 1B).
The helical content calculated from the CD spectra was 77%
(Fig. 1C), in agreementwith the 78% seen in the structure of free
RLIP76 RBD (Ref. 33; PDB code 2KWH). CD analysis of the two
synthetic peptides revealed that Peptide 1 was 50% helical in
solution, whereas Peptide 2was only 4%helical (Fig. 1,B andC).
The helical content of the residues equivalent to Peptides 1 and
2 in the context of the entire RBD is 96 and 53%, respectively.
Therefore, the helices in both peptides are destabilized when
they are not in the context of the coiled-coil. Peptide 1, how-
ever, clearly retains some helical propensity in isolation and
presumably is in equilibrium between structured and unstruc-
tured states. Conversely, Peptide 2 shows little propensity to
form any helix when it is removed from the coiled-coil, and its
CD spectrum is characteristic of a random coil (Fig. 1B).
The binding of the RLIP76 RBD, Peptide 1, and Peptide 2 to
RalB was investigated using isothermal titration calorimetry
(ITC). TheRLIP76RBDcoiled-coil bound toRalBwith an affin-
ity of 1.9 M (Fig. 2A, Table 1) and with a similar affinity (4.6
M) to RalAGMPPNP (data not shown). The interaction
appears to be driven by a relatively large, favorable enthalpic
FIGURE 1.Design and synthesis of RLIP76-basedpeptides.A, the structure of the RLIP76 RBDbound to RalBGMPPNP (PDB code 2KWI) revealed key binding
residues. RalB is colored blue, and the two switch regions are labeled. RLIP76 is colored as follows: the segment of the N-terminal helix that contacts RalB is
colored green, the rest of the N-terminal helix is gray. The C-terminal helix is colored pink, and the side chains of residueswhosemutation reduced the binding
to RalB5-fold (17) are colored yellow. The peptides synthesized are shown schematically, with the same color coding and the staple represented as a single
i, i4 olefin link. B, CD spectra of the RLIP76 RBD and the peptides generated in this study. C, sequences of the peptides used in this study and helicity were
calculated from analysis of CD data of the RLIP76 RBD and the peptides. Several peptides were synthesized containing all-hydrocarbon staples of various
lengths in different positions (indicated by X). Peptides 1 and SP1-SP5were based on the sequence of the secondRLIP76 RBD-helix sequence. Peptides 2 and
SP6 were based on the first -helix. The -helicity of the peptides assessed using CD spectroscopy confirmed that several of the stapled peptides synthesized
are more helical than the unstapled version of the peptide.
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FIGURE 2. Peptides corresponding to helix 2 are sufficient to bind to Ral proteins. Representative data from ITC experiments are shown for titrations of the
RLIP76RBD intoRalBGMPPNP(A), Peptide1 intoRalBGMPPNP(B), Peptide2 intoRalBGMPPNP(C), Peptide1 intoRalAGMPPNP(D), andPeptide1 intoRac1GMPPNP
(E). The parameters for the fit for these individual experiments are shown in each panel. For the average parameters obtained fromseveral experiments, see Table 1.
TABLE 1
Summary of binding parameters obtained from ITC for RLIP76 and peptides titrated into Ral proteins
The value obtained from an orthogonal assay, FP, is included for the tightest binding peptide.
Binding partners Kd H TS Na
M kcal mol1 kcal mol1
RalBGMPPNP RLIP76 RBD (n 2b) 1.9 0.07c 17.5 1.8 9.6 1.8 0.9
RalBGMPPNP Peptide 1 (n 4) 29.8 7.3 1.6 0.6 4.6 0.7 1.1
RalAGMPPNP Peptide 1 (n 3) 43.0 10.8 1.8 0.9 4.2 0.9 1.0
RalBGMPPNP SP1 (n 3) 4.7 1.6 (5.6 0.3d) 0.7 0.4 6.6 0.2 1.0
RalBGMPPNP SP2 (n 2) 10.3 2.3 0.8 0.0 6.0 0.1 1.1
RalBGMPPNP SP3 (n 3) 53.3 17.8 0.7 0.3 5.1 0.5 0.9
RalBGMPPNP SP4e 50.8 0.4 5.5 1.0
RalBGMPPNP SP5 (n 3) 24 Not fitted Not fitted Not fitted
a Stoichiometry.
bNumber of experiments.
c S.D. of value obtained from multiple experiments.
d Value obtained from FP.
e Peptide behaved poorly in assays and showed low heat changes: data from a single experiment only.
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term that counteracts the unfavorable entropy loss that occurs
when the two domains come together. Peptide 1 also bound to
RalB but with a lower affinity. The Kd was around 30 M, an
order of magnitude weaker than the full coiled-coil domain of
RLIP76RBD (Fig. 2B, Table 1). In contrast, Peptide 2 showedno
heat changes when titrated into RalB under the same condi-
tions, supporting the idea that most Ral binding contacts occur
through RLIP76 RBD 2 (Fig. 2C). Encouragingly, whereas ITC
showed that Peptide 1 also bound to RalA, with aKd 43M (Fig.
2D, Table 1), it showed no interaction with the Rho-family
GTPase Rac1 (Fig. 2E), indicating that binding of this single
helix is selective for Ral small G proteins.
The ITC data for Peptide 1 revealed that when this peptide
binds to RalA and RalB, the 	S term is positive, in contrast to
the entropy loss that was observed when RLIP76 RBD and
Ral proteins interact. This favorable entropy change
increases the binding affinity, which would otherwise be
drastically reduced by the smaller enthalpic gain when the
peptides bind (Table 1).
A Peptide Based on RLIP76 RBD 2 Binds to RalB on the
Same Interface as RLIP76—Given the altered thermodynamics
of the interaction, it is possible that Peptide 1 binds to a differ-
ent region of the Ral proteins. To ascertain whether Peptide 1
binds in a similar manner as the RLIP76 RBD, 1H,15N HSQC
NMR experiments were used to map the binding surface on
RalB utilized by Peptide 1. The HSQC spectra of uniformly
15N-labeled RalBGMPPNP were recorded both alone and in
the presence of increasing amounts of Peptide 1. The addition
of Peptide 1 caused several RalB peaks to shift and in some cases
to lose intensity (Fig. 3A), which is consistent with a mixture of
fast and intermediate exchange on the NMR timescale. This is
likely to be due to the switch regions of RalB undergoing con-
formational exchange when in the complex with the peptide. A
titration was performed at a range of RalB:Peptide 1 ratios from
1:0 to 1:8, which along with the previously reported backbone
assignment (41) allowed most of the cross-peak positions to be
tracked. Themajority of the peaks in the peptide complex were
assigned, and their positions were compared with those of the
peaks corresponding to the same residues in the RalB-RLIP76
RBD complex. Comparison of the HSQC spectra of free
RalBGMPPNP with RalBGMPPNP-Peptide 1 and RalB
GMPPNP-RLIP76 RBD shows that those peaks that shifted
tended to move in the same direction in both complex spectra
(Fig. 3A). For example, Arg-52, which experienced a relatively
large shift, moved in the Peptide 1 complex to a position very
close to that of the Arg-52 cross-peak in the RLIP76 RBD com-
plex. The peak positions in free RalBGMPPNP and in
RalBGMPPNP-Peptide 1 were used to calculate the overall
chemical shift change (Fig. 3B). The changes are concentrated
in the N-terminal half of the RalB protein, which includes the
two nucleotide-sensitive switch regions. The residues that
experienced a significant shift change (larger than the S.D. of all
changes) weremapped onto the RalB structure (Fig. 3C). These
included several residues that are unlikely to directly contact
Peptide 1, because they are buried in the free RalB structure
(42). These shift changes, which also occurredwhen theRLIP76
RBD was titrated into RalB, are indicative of subtle conforma-
tional rearrangements that are often observed when small G
proteins such as RalB bind to their effectors.6 The solvent
accessibility of the RalBGMPPNP residues was assessed using
NACCESS (43). Residues that are shifted and are at least 50%
solvent-exposed, are highlighted in Fig. 3C. All of these residues
are within, or close to, the switch regions, andmost of them are
in direct contact with the C-terminal helix of RLIP76 RBD in
the complex (Fig. 3,C andD). Two residues that shift but do not
contact RLIP76 are Val-40RalB and Glu-41RalB. These are at the
beginning of switch 1, whereas Asp-49RalB at the opposite end
of the same switch is in direct contact. The structure and
dynamics of the whole switch region changes in the RLIP76 com-
plex, and the chemical shifts of Val-40 and Glu-41 are likely to be
sensitive to this. The cross-peaks for most of switch 1 are not vis-
ible in the spectra of freeRalBGMPPNP, so it is not possible to see
changes for other residues within the same loop. Overall, the cor-
relation between cross-peak positions in the RalBGMPPNP-Pep-
tide 1 and RalBGMPPNP-RLIP76 RBD spectra along with the
positions of the residues that exhibit the largest chemical shift
changes indicate that the contact surface for Peptide 1 on RalB is
identical to that of the RLIP76 RBD helix 2.
Design and Synthesis of RLIP76-based Stapled Peptides—
Having established that an RLIP76 RBD-based 2 peptide
could selectively bind to Ral in an analogous manner to the
RLIP76 RBD, we sought to improve its binding affinity. Chem-
ical stapling of peptides has been shown to increase their heli-
city and often enhances their binding to target proteins (36).
Stapled peptides were synthesized using a well established solid-
phase peptide synthesis method for incorporation of all-hy-
drocarbon staples (44). Two unnatural amino acids containing
-methyl, -alkenyl side chains were introduced into the pep-
tide sequence and the staple covalently formed by ruthenium-
catalyzed ring-closing metathesis (Fig. 1, A and C). Five stapled
peptides were designed based on RLIP76 RBD 2 (SP1-SP5),
as Peptide 1 had already been confirmed to bind Ral. One sta-
pled peptide was also designed based on RLIP76 RBD helix 1
(SP6) to investigate whether increased secondary structure in
Peptide 2 could facilitate Ral complex formation. Examination
of theRalBGMPPNP-RLIP76RBD structure (33) togetherwith
computational and experimental alanine scanningmutagenesis
data (17) revealed those RLIP76 RBD residues that were the
most important for Ral binding (Fig. 1A). These included three
residues in helix 1 (Leu-409, His-413, and Leu-416) and five
residues in helix 2 (Leu-429, Trp-430, Arg-434, Thr-437, and
Lys-440). Individual mutation of any of these residues to Ala
reduced the binding affinity of RLIP76 RBD for RalA or RalB
5-fold (17). These vital binding residues were retained in
the peptide sequences, and the chemical staples were posi-
tioned on the opposite face of the -helix to allow these key
residues to drive complex formation (Fig. 1, A and C). Pep-
tides were synthesized with different staple lengths and sta-
ple positions to enable screening for optimum binding. SP1,
SP2, and SP3 contained a single i, i4 staple, that was placed
in various positions along the 2 helix. SP6, based on helix
1 and the interhelix loop, only included three turns of the
-helix. This peptide also contained a single i, i4 staple;
6 D. Owen and H. R. Mott, unpublished observations.
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however, only a single staple position was tested, as other
positions would potentially disrupt the structure of the loop.
SP4 and SP5 were also based on helix 2: SP4 contained one
i, i7 staple, and SP5 was doubly stapled, with two i, i4
linkages (Fig. 1C). All peptides were acetylated at the N ter-
minus and included a C-terminal amide bond. After purifi-
HKVIMVGSGGVGKSALTLQFMYDE
HKLVVVGGGGVGKSALTIQFIQSY
**:::** *********:**:   
FVEDYEPTKADSYRKKVVLDGEEV
FVSDYDPTIEDSYTKICSVDGIPA
** **:**  *** *   :**   
QIDILDTAGQEDYAAIRDNYFRSG
RLDILDTAGQEEFGAMREQYMRAG
::*********:: *:*::*:*:*
8.58.68.78.88.99.09.1
121.5
122.0
122.5
123.0
123.5
124.0
124.5
Y51
K16
R52V62
N128
I95
V20
K27
K16
K16
R52
R52
Y51Y51
V20
V20
RalB alone
RalB + Peptide 1
RalB + RLIP76 RBD
I95
K27
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
Residue Number
0
0.1
0.2
0.3
0.4
0.5
Ch
em
ica
l S
hi
ft 
Pe
rtu
rb
at
io
n
20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180
sw1 sw2
A
B
C
+ *+*
* + ** **
++
*
RalA/B
R-Ras
RalA/B
R-Ras
RalA/B
R-Ras
15 38
39 62
63 86
30 53
54 77
78 101
N-terminal helix
C-terminal helix
Tyr36
Val40
Glu41
Asp49
Ile78
Asn81
Ser85
Arg52
sw1
sw2
D
FIGURE 3. Peptide 1 binds to RalB in an analogous manner to RLIP76 RBD. A, section of 1H,15N HSQC NMR spectra of 15N RalBGMPPNP alone (blue) and in the
presence of excess Peptide 1 (red) or RLIP76 RBD (black). The addition of Peptide 1 caused themovement of several peaks, all ofwhich also shifted upon the addition
ofRLIP76RBD. Thechanges in cross-peakswhenPeptide1 is added toRalBare smaller than thoseobservedwhenRLIP76RBD is addedbut thepeaks shift in the same
direction (see thedotted lines e.g.Lys-16, Val-20, Lys-27, Tyr-51, andArg-52). Peaks thatdonot shiftwhenRLIP76RBD is added (e.g.Asn-128)donot shiftwhenPeptide
1 is added. B, the chemical shift changes are plotted for each residue of RalB. The secondary structural elements are shown above the graph, where -strands are
representedbyarrows, and-helices are representedby cylinders.Red lines indicate the locationsof the twoswitch regions. Thedashedblue line shows thepositionof
the average chemical shift change (0.047), and the solid green line shows the S.D. of the chemical shift changes (0.068). C, RalB residues that shifted by1 S.D. upon
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identifiedwith a label.D, sequence alignment of RalA/B andR-Ras in the region that interactswith RLIP76 RBD. RalA andRalB have identical sequences in this region.
Residue conservation is denoted below the alignment: * identical, : conservative substitution. Ral residues surrounded by a gray box interact with the N-terminal
helix of RLIP76 RBD (helix 1); residues coloredmagenta interact with the C-terminal helix of RLIP76 RBD (helix 2). The symbols above the RalA/B sequence denote
residues that formhydrogenbondsor saltbridges involvingbackbone () or side-chain (*) atomsofRalB. Thesymbolsarecoloredgray forRLIP76RBD1 interactions
andmagenta for2 interactions. Red lines indicate the locations of the two switch regions.
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cation, the helicity of the stapled peptides was determined by
CD spectroscopy (Fig. 1, B and C). Incorporation of the sta-
ples increased the helicity of most of the RLIP76 RBD pep-
tides compared with their unstapled counterparts: SP1, SP3,
SP4, and SP5 showed extremely high helicity (80–90%),
much more than the unstapled Peptide 1, and close to the
90% expected if the peptides were to adopt the same struc-
ture as 2. SP2 was the least helical of the 2-based stapled
peptides and had the same helicity as the unstapled Peptide
1, suggesting that the staple at this position does little to
stabilize the helix. Stapling of the unstructured Peptide 2
also significantly increased its helicity, although SP6 was still
only 57% -helical, less than the 75% expected if the pep-
tide had the same structure as the equivalent sequence in the
RLIP76 RBD.
SP1 Binds to RalB with Increased Affinity Compared with
Unstapled Peptide 1—Stapled peptide binding to RalB
GMPPNP was investigated using ITC, as for the unstapled
peptides (Fig. 4). All of the stapled peptides based on the
RLIP76 RBD 2 sequence (SP1-SP5) were able to bind RalB,
but the stapled analogue of 1, SP6, did not exhibit any heat
changes despite its increased helicity. This suggests that the
binding interactions made between RLIP76 RBD 1 and
RalB are not strong enough to enable complex formation in
the absence of the 2 helix. The 2-based peptides SP3, SP4,
and SP5 bound RalB with a Kd 16–53 M (Table 1), which is
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FIGURE 4. Peptide stapling can increase affinity of RalB binding. ITC data for stapled peptides titrated into RalBGMPPNP at 298 K: SP1 (A), SP2 (B), SP3 (C),
SP4 (D), SP5 (E), and SP6 (F). The parameters for the fit for the individual experiments are shown. For a summary of the parameters from several experiments,
see Table 1. SP5 could not be accurately fit, although the heat changes observed indicate that the peptide does bind. A lower limit on the Kd is given, but no
reliable parameters could be obtained.
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similar to the affinity of the unstapled Peptide 1 (30 M).
Compared with Peptide 1, SP1 and SP2 displayed enhanced
affinity, with Kd values 4.7 M and 10.3 M, respectively.
The binding of the stapled peptides was characterized by
similar	H terms (of the order of 1 kcal/mol), implying that the
nature of the interfaces may be similar (Fig. 4, Table 1). The
exception was SP4, which has the longer, i, i7 staple, and was
characterized by very small heat changes and non-reproducible
data in the ITC experiments. This implies that SP4 binds using
predominantly hydrophobic interactions and, therefore, may
not utilize the same binding mode as the other peptides. Simi-
larly, SP5, which has a double staple, bound weakly, and the
data could not be accurately fitted. The stapled peptides had
more favorable entropy of binding compared with the
unstapled Peptide 1, and the enhanced binding of SP1 and SP2
is entirely due to the increase in 	S.
SP1 Is Selective for Active Ral and Binds Competitively with
Ral Effector Proteins—As SP1 bound to RalB with the highest
affinity, this peptide was taken forward for further investiga-
tion. N-terminally fluorescein-labeled FITC-SP1 and FITC-
Peptide 1 were synthesized for fluorescence polarization (FP)
assays. The use of an orthogonal assay tomeasure peptide bind-
ing was also useful to validate the results obtained with ITC.
Direct binding FP assays showed that SP1-boundRalBwith aKd
value of 5.6 M, similar to that measured by ITC (Fig. 5A). The
binding of Peptide 1 measured by FP was too weak to obtain an
accurate fit (Fig. 5B), which placed the Kd at 50 M, in line
with the value measured by ITC (Table 1). We also tested the
binding of FITC-SP1 to RalAGMPPNP and found that it
bound but with a slightly lower affinity than to RalB
GMPPNP, with a Kd of 14.2 M (Fig. 5C). This is in agree-
ment with the lower affinities that we observed when
unstapled Peptide 1 or the RLIP76 RBD was titrated into
RalAGMPPNP in ITC experiments.
To investigate the specificity of SP1 for Ral proteins, we
examined its ability to bind to R-Ras, which is another small G
protein in the Ras family. This is a stringent test of specificity, as
R-Ras and RalB are both in the Ras family, have a sequence
homology of 64%, and are conserved in the effector binding
region (Fig. 3D). FITC-SP1 bound to R-RasGMPPNP but with
an affinity of 30 M, 5-fold weaker than RalB (Fig. 5A). The
affinity of FITC-Peptide 1 for R-RasGMPPNP could not be
determined accurately but again was weaker than that of Pep-
tide1 for RalBGMPPNP (Fig. 5B).
Attempts were made to perform chemical shift mapping
experiments with SP1 and 15N-labeled RalBGMPPNP, analo-
gous to those shown in Fig. 3. It was, however, not possible to
find conditions in which both SP1 and RalB were stable at suf-
ficiently high concentrations for NMR. As the peptides were
designed based on helices from a Ral effector and the NMR
chemical shift mapping had suggested that Peptide 1 bound
close to the switch regions, we reasoned that the peptide bind-
ing should be nucleotide-dependent. Nucleotide-dependent
binding of SP1 to Ral would also imply that SP1 binds to Ral in
the same regions as Peptide 1. When RalAGDP was titrated
into FITC-SP1 (Fig. 5C) no significant binding was observed,
indicating that SP1 binding to Ral is dependent upon the GTP-
bound conformation of the switch regions. Therefore, as is the
case for GTPase effector proteins, SP1 preferentially binds
active, GTP-bound Ral over the inactive, GDP-bound state.
FITC-SP1 FITC-Peptide 1
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FIGURE 5. FITC-SP1 binding to Ral is specific, GTP-dependent, and competitive with Ral effectors. A, fluorescence polarization assays using FITC-labeled
SP1 confirm that SP1 binds RalB (Kd 5.6 0.3M, solid line). SP1 also boundweakly to R-Ras (Kd 30.0 18.0M, dashed line). B, Peptide 1 boundweakly to RalB
andeven less tightly to R-Ras. Affinitywas too low for reliable fitting.C, SP1binds RalAGMPPNPwith similar affinity to RalBGMPPNP (Kd14.28.2M, solid line)
but did not show significant binding to RalAGDP (dashed line). D, competition fluorescence polarization assays showed that both RLIP76 (solid line) and Sec5
(dashed line) displaced FITC-SP1 from RalB, suggesting FITC-SP1 binds to RalB on an overlapping surface. Data were fitted to give IC50 8.2 2.6M (Sec5 RBD)
and IC50 2.0 1.2M (RLIP76 RBD). All FP experiments were performed in duplicate, and error bars show the S.D. of the duplicates.mP, millipolarization units.
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To determine whether effector proteins could compete with
SP1 for binding to RalB, a competition FP assay was performed.
Increasing amounts of the RLIP76 RBD were titrated into a
preformed complex of RalBGMPPNP-FITC-SP1. The result-
ing decrease in FP signal (Fig. 5D) indicates that FITC-SP1 and
the RLIP76 RBD bind competitively to RalBGMPPNP. The
RLIP76 RBDwas able to fully displace FITC-SP1with an IC50 of
2.0 M, which is comparable with the Kd for RalBGMPPNP-
RLIP76 RBD measured by ITC. This indicates that the peptide
andRLIP76RBDuse the same interface to bindRalBGMPPNP.
We were interested in exploring whether other Ral effectors
could also compete with SP1 for RalBGMPPNP binding. The
Sec5 RBD binds to Ral proteins with a higher affinity than
RLIP76; both RalA and RalB bind Sec5 RBD with a Kd of100
nM (42). When the Sec5 RBD was titrated into the
RalBGMPPNP-FITC-SP1 complex, the FP signal was reduced.
However, Sec5 did not cause complete loss of the FP signal even
at high concentrations and resulted in an IC50 of 8.2 M, i.e.
much higher than its Kd. This indicates that although there is
some overlap in the binding sites of SP1 and Sec5 RBD, even at
high Sec5 concentrations some binding remains between
FITC-SP1 and RalBGMPPNP. This can be explained by the
observation that the RLIP76 RBD binds to both switch regions
of RalB (33), whereas Sec5 RBD only contacts switch 1 (18).
Therefore, the Sec5 RBD binding to switch 1 is unable to dis-
place SP1 completely, which can continue to contact switch 2
even in the presence of Sec5. Taken together, the evidence indi-
cates that FITC-SP1 binds in an analogous manner to 2 of the
RLIP76RBD,which contacts both switch regions and cannot be
fully displaced by the Sec5 RBD.
FITC-SP1 Can Enter Mammalian Cells—For stapled pep-
tides to have experimental or therapeutic value they must be
able to access their intracellular targets. To assess the cell pen-
etrating properties of RLIP76 RBD-based peptides, we moni-
tored the cellular uptake of FITC-Peptide 1 and FITC-SP1
using confocal microscopy. HEK293T cells were treated with
10 M FITC-Peptide 1, FITC-SP1, or FITC alone overnight at
37 °C and fixedwith formaldehyde before imaging (Fig. 6,A and
B). Consistent with previous studies on stapled peptides (36, 37,
45, 46), robust penetration of SP1 into cells was observed. In
contrast, uptake of FITC alone or the unconstrained FITC-Pep-
tide 1 was not detectable in any cells. These data also indicate
that the stapled peptide is stable for at least 16 h. Single-cell
images indicate that FITC-SP1 localizes throughout the cell,
entering the nucleus as well as diffusing through the cytosol
(Fig. 6B). Encouragingly, the cells treated with FITC-SP1 were
observed to be in a similar state of health and confluency as the
control cells, suggesting that the peptide is not inherently toxic.
Oncewe had established cellular uptake of SP1, wewanted to
confirm that the inhibition of Ral-effector interactions that we
had already demonstrated in vitro for the stapled peptide were
maintained in a cellular context. To judge this, we examined the
ability of SP1 to inhibit co-immunoprecipitation of RalB with
an effector protein. We incubated HEK293T cells in the pres-
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FIGURE 6. FITC-SP1 can entermammalian cells and inhibits the interaction betweenRalB and Sec5. Shown arewide-field (A) and single-cell images (B) of
HEK293T cells treated with 10 M FITC-Peptide 1, 10 M FITC-SP1, or 10 M FITC control overnight. Chemical stapling enables FITC-SP1 to penetrate the cell
membrane and localize in both the cytosol and nucleus. C, SP1 disrupted RalB-Sec5 interaction in cells. HEK293T cells were treated for 24 h with SP1 and SP6
as indicated. The numbers above the Western blot represent the relative intensities of the Sec5 band, normalized to the no-peptide control. Endogenous RalB
was immunoprecipitated (IP)withmouse anti-RalB antibody. Immunoblottingwas conductedwithprimary antibodies against RalB andSec5. *marks theband
specific to Sec5. Ab, mouse anti-RalB antibody alone.WCL, whole cell lysate.
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ence or absence of SP1, immunoprecipitated endogenous RalB,
and immunoblotted for the presence of Sec5. SP6, the stapled
helical peptide based on helix 1, which showed no heat
changes in ITC experiments (Fig. 4F), was used as a control.We
used Sec5 to investigate whether SP1 acts as a pan-RalB inhib-
itor in cells with similar activity to that which we had already
observed in vitro. Endogenous Sec5 was observed to co-immu-
noprecipitate with RalB in the absence of peptide (Fig. 6C), but
the interaction was almost completely inhibited by SP1 24 h
after treatment. Interestingly, SP6 also appeared to attenuate
the RalB-Sec5 interaction, although not as strongly as SP1. This
suggests that even though it showed no heat changes in the ITC
experiments, SP6 exhibits some low affinity binding to RalB.
We can, therefore, conclude that SP1 enters cells, and once it is
intracellular it retains the ability to inhibit RalB interactions
with its downstream effector proteins.
SP1 Can Inhibit RalB-driven Autophagosome Assembly in
Cells—We next sought to examine whether SP1 retained the
biological activity of the RLIP76 RBD and could interfere with
Ral signaling in cells. Previous studies have demonstrated the
involvement of RalB in nutrient deprivation-induced autopha-
gosome assembly through its interaction with the downstream
effector Exo84 (35). RalB is localized to nascent autophago-
somes and is activated in response to nutrient deprivation. In its
active conformation, RalBGTP binds directly to its effector
Exo84, inducing the assembly of catalytically active ULK1 and
Beclin1-VPS34 complexes on the exocyst, which drive isolation
membrane formation and maturation. Thus, RalB signaling is
necessary and sufficient to engage autophagy. In contrast, RalA
has no involvement in the control of autophagy, so monitoring
the effects of SP1 on autophagy specifically reveals the effects of
its inhibition of RalB. Autophagosome assembly can be moni-
tored through the loss of the marker LC3, which is first
recruited to autophagosomes before its degradation in
autophagolysosomes (Fig. 7,A and B). Exogenous expression of
the RLIP76 RBD inhibits RalB-Exo84 complex formation and
prevents autophagosome formation and maturation (35). To
investigate whether SP1 had the same effect, HeLa cells stably
expressing GFP-LC3 were treated with the cell-permeable SP1
for 24 h and assayed for autophagosomal flux with quantitative
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microtiter plate-based assays. SP1 but not SP6 exposure
resulted in dose-dependent inhibition of GFP-LC3 turnover
that was not reversed by nutrient starvation, indicating robust
inhibition of autophagosomal maturation at 20 M SP1 (Fig.
7C). These observations imply that SP1 is able to penetrate cells
and achieve a sufficiently high intracellular concentration to
bind to RalB and inhibit its biological activity. To confirm that
the effects observed were due to the interaction between SP1
and RalB, the localization of TFEB was evaluated. TFEB is a
direct mTORC1 substrate that is sequestered in the cytosol
under nutrient replete conditions (47, 48). Nutrient starvation
results in mTORC1 inactivation and consequent translocation
of TFEB to the nucleus where it induces adaptive gene expres-
sion programs. TFEB localization was unimpaired in SP1-
treated cells (Fig. 7D), demonstrating that the SP1-dependent
inhibition of autophagosome maturation is unlikely to be
through non-selective disruption of cellular responses to nutri-
ent deprivation.
Discussion
The Ras signaling pathway has been proven to be a key driver
of numerous cancers and is, therefore, a crucial anti-cancer
drug discovery target. The difficulty in obtaining drug-like
compounds that inhibit Ras itself has led to broader targeting of
downstream Ras pathways, including the kinases Raf and PI3K.
These efforts have been hampered by unexpected discoveries;
the first class of Raf inhibitors turned out to activate the path-
way in Ras-driven cancers (10), whereas MEK and PI3K inhib-
itors are also less efficacious due to the presence of feedback
loops and poor tolerance (11). The third main Ras-driven sig-
naling pathway activates the small GTPases RalA and RalB
through the RalGEFs. Evidence indicates that this pathway is
equally important in conveying signals from oncogenic Ras to
drive tumorigenesis and is, therefore, a valuable therapeutic
target (1). This signaling route has not been as extensively stud-
ied as the Raf and PI3K systems and does not exhibit as many
conventionally exploitable targets. In fact until very recently
there have not been any chemical inhibitors reported that act
on this branch of the Ras cascade. Recently, a potential allos-
teric site was identified on RalA and used as the basis for a
virtual small molecule screen. This generated hits that inhibit
RalA and RalB by binding to the small G proteins in their GDP-
bound form, locking them in their inactive conformation.
These molecules have biological activity in cell lines and are
also efficacious in mouse xenografts driven by K-Ras/Ral, dem-
onstrating the utility of Ral inhibition for therapeutic gain and
representing an exciting step forward in cancer therapeutics
(32). Here, we have used our structure of the RalB-RLIP76 RBD
complex to design and synthesize all-hydrocarbon-stapled pep-
tides that bind to both RalA and RalB in the active, GTP-bound
conformation and compete with their effector proteins.
We used ITC to determine the affinities and thermodynam-
ics of binding of the peptides. Interestingly, we obtained aKd of
1.9 M for the RalBGMPPNP-RLIP76 RBD complex by ITC,
10-fold higher than the Kd of 184 nM that we had previously
determined by scintillation proximity assay (33). There are sev-
eral likely reasons for these differences. First, different tech-
niques used to determine affinities often yield different Kd val-
ues. This has been shown for other Ral-effector complexes; for
example RalAGMPPNP binding to Sec5 RBD had a Kd of 137
nMmeasured by ITC (18) but aKd of 10 nMmeasured by surface
plasmon resonance (19). We also found that Cdc42GMPPNP
binding to PAK gave lower affinities with ITC (Kd 150 nM) than
the scintillation proximity assay (Kd 10 nM) (49). The difference
in the RalB-RLIP76 RBD affinitymay also be affected by the use
of the nucleotide used in the different experiments. In the ITC
experiments, RalBwas bound to the nucleotide analogueGMP-
PNP,whereas a scintillation proximity assay utilized 3H-labeled
GTP. All the peptides synthesized in this study were examined
for binding by ITC, so their relative values can be compared.
Furthermore, the affinities measured using FP for the peptides
were similar to those obtained by ITC, allowing comparison
between the affinities measured with these techniques.
We have shown that a peptide based on a single helix from
RLIP76 (Peptide 1) is sufficient to bind Ral, albeit with an14-
fold weaker affinity than the full coiled-coil domain that com-
prises the RBD. NMR mapping indicates that Peptide 1 inter-
acts with RalB at the same binding interface as RLIP76 RBD, so
the reduction in affinity is due to the smaller peptide making
fewer contacts with Ral rather than to a different mode of bind-
ing. ITC was used to measure the affinities, but it also yielded
useful information about the thermodynamics of the interac-
tions (Table 1). The interaction between RalBGMPPNP and
the full RLIP76 RBD is driven solely by a large negative 	H, as
the entropy change is in fact unfavorable. An analysis of the
interactions between the two proteins suggests that the inter-
face comprises a mixture of hydrogen bonds/salt bridges and
hydrophobic interactions, which involve both -helices of
the RLIP76 RBD. Presumably the hydrophobic interactions
between the two proteins are not sufficiently numerous to off-
set the entropy loss on association. In contrast, when the pep-
tides bind, the enthalpy term is reduced 10-fold or more
(although it is still negative), but the entropy term is now posi-
tive (Table 1). Some of the change in enthalpy compared with
the full RBD binding is likely to be due to the loss of the three
hydrogen bonds involving helix 1 predicted from the struc-
ture: His-413(N)–Tyr-82(OH), Leu-416(CO)–Asn-81(H),
Gln-417(H)–Asp-74(CO), which are not present in the pep-
tide complexes. The switch in the entropic term from negative
in the full RBD to positive in the peptides is probably due to the
larger number of exposed hydrophobic side chains in the pep-
tides, which lowers the entropy of the free peptides. The stapled
peptides bindmore tightly than the unstapled versions because
the entropic term is even more favorable, and apart from SP4
(which gave poor, non-reproducible data),	S is proportional to
the affinity (Table 1). Peptide stapling reduces the entropic cost
of the peptide folding upon binding by forcing the helix to be
pre-formed. The subtle differences between the stapled pep-
tides may be due to slight conformational differences when the
staple position is moved. These could change the extent of bur-
ial of side chains in the interface.
The helicity of the stapled peptides shows little obvious cor-
relation with their affinities. The helical content of SP1, SP3,
SP4, and SP5 is almost equivalent, whereas SP2, which has the
second tightest binding, is no more helical than Peptide 1 (Fig.
1C). The helical content estimated by CD is, however, the aver-
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age in solution. It is reasonable to assume that Peptide 1 exists
in an equilibriumbetweenhelical and unstructured, and that, as
it is 50% helical, the two populations are approximately equal.
Binding to RalB then pushes the equilibrium to the helical state.
In SP2, on the other hand, the stapling ensures that the center of
the peptide is helical, so that at least part of the peptide is helical
all of the time. This shorter helix would then act as a nucleation
site for the formation of the remainder of the helix on binding.
For peptides such as SP3, which exhibits high helicity but low
affinity, we can speculate that the staple position has locked the
side chains into a position where they can no longer make
favorable interactions with RalB. It is noteworthy that SP3 and
SP4, neither of which binds tightly, both have their staple posi-
tioned behind the Trp within the peptide. Mutation of Trp-430
in the context of the RLIP76 RBD knocks out binding com-
pletely (17), and the structure shows that this residue makes
extensive interactions with RalB (33). It is likely that the rigidity
imposed by stapling across the back surface of this Trp restricts
at least some of these interactions.
The most potent RLIP76 RBD 2-based stapled peptide
(SP1) bound to RalB with a 5-fold increase in affinity over the
unstapled peptide. Previously published studies on stapled pep-
tides have reported affinity increases between 2- and 100-fold,
depending on the protein target (36, 37). The 5-fold increase
noted here, therefore, is rather amodest effect. However, in this
case the native unstapled peptide is already significantly helical
(unlikemany other peptides) and has a reasonable affinity com-
pared with that of the RLIP76 RBD. The final affinity of the best
stapled peptide is only2.5-foldweaker than the complete pro-
genitor domain, the RLIP76 RBD, and as such, SP1 provides an
excellent starting point for further optimization. Interestingly,
the small molecule inhibitors identified for Ral also have aKd of
5–8 M and are still effective inhibitors in both cell culture
and animal models (32). These low M Kd values reflect the
difficulty in designing chemical inhibitors for Ral proteins and
highlight the importance of our peptide.
Constrained peptides have already been designed to bind to
small G proteins of the Ras superfamily. Ras itself has been
targeted with stabilized -helical peptides that were based on a
helix from the exchange factor SOS. Peptides stabilized by the
hydrogen bond surrogate method (39) bound to RasGDP with
a Kd of 160 M, 10-fold weaker than the catalytic domain of
SOS. On the other hand, hydrocarbon-stapled peptides based
on the same SOS helix bound to K-Ras with an affinity of
around 0.1 M but were not selective for the GTP-bound form,
as expected for a peptide based on an exchange factor (40).
Hydrocarbon-stapled peptides based on Rab-binding proteins,
including effectors and exchange factors, have been screened
against several members of the Rab small G protein family. Sev-
eral of these bound preferentially to nucleotide-free Rabs, but a
Kd of 22 M was obtained for the most potent stapled peptide
with GMPPNP-bound Rab8a, which was also selective for this
Rab isoform (50).
We exploited the helical nature of an effector protein in this
work to specifically target the GTP-bound form of the Ral pro-
teins on the basis that this is the form that is downstream of
oncogenic Ras and so is active in a disease scenario. We have
shown that this is a viable approach, as the highest affinity pep-
tide was indeed specific for the active Ral proteins and showed
no interaction with the GDP-bound forms. Can this approach
be applied to other small G proteins? For Ras itself it is difficult
to envisage, as all the known effectors utilize an intermolecular
-sheet to bind the G protein (for review, see Ref. 34). Apart
from Ras, the largest structural class of effectors for small G
proteins is actually that which bind using a helical pair. We
recently classified these into six subclasses, based on their helix
orientations, which cover interactions between effectors and
members of the Ras, Rho, Arf, and Rab families (34). In several
cases one of the helices dominates, making the majority of the
interactions with the nucleotide-sensitive switch regions, and
therefore the relevant small G proteins, open to this approach
to inhibitor design. Representative examples from five of the six
classes, where one helix makes the most interactions, are RalB-
RLIP76, Arf1-GGA, Rac1-PRK1, Arl1-Arfaptin1, and Arf6-
JIP4. Stabilized helical peptides based on effectors may, there-
fore, be useful starting points for design of molecules that bind
(and inhibit)members of theArf andRho families aswell as Rab
and Ral.
The stapled peptides that we have designed bind to the
nucleotide-sensitive switch regions of Ral. These regions, as
well as being responsible for effector binding, are the sites of
interaction with the GEFs and GAPs, the regulators of the G
proteins. We tested whether SP1 bound competitively with Ral
effectors and found that it could be fully displaced by RLIP76
and only partially displaced by Sec5. This indicates that SP1
binds to both switch 1 and switch 2. The recent structure of Ral
with a GEF protein (Rlf) shows that switch 2 is involved in the
GEF interaction and is also important for Ral versus Ras selec-
tivity (25). There are currently no structures of Rals in complex
with cognate GAPs, but the RalGAP proteins have the closest
homology with RapGAPs, and a Rap1bRap1GAP complex
shows that both switch regions of the Rap protein are involved
in the interaction (51). As our peptides do not bind to the GDP-
bound form of Ral, they should not compete with GEF proteins
for binding, but they are likely to bind competitively with the
GAP proteins. This implies that they would not prevent Ral
proteins being activated (i.e. becoming GTP-bound) in the cell,
but as the peptides would be competitive with GAP binding,
they could prevent deactivation. Nevertheless, we have demon-
strated here the important overall effect of SP1 in cells, which is
to prevent Ral signaling by competing with effector binding.
Furthermore, GTP-specific peptides would be particularly use-
ful in cells that have reduced RalGAP activity, for example inva-
sive bladder cancer cell lines (27).
Interestingly, we found that RalAGMPPNP binding to both
Peptide 1 and SP1 was of a lower affinity than RalBGMPPNP
binding to the same peptides. The peptides were designed
based on the structure of RalBGMPPNP with RLIP76 RBD.
Although the RalAGMPPNP and RalBGMPPNP sequences
are identical in the regions that bind to RLIP76, mutagenesis of
the RLIP76 RBD has revealed some isoform differences (17). Of
interest is the observation that mutation of Leu-412 in helix 1
to Ala reduces RalA binding 4-fold but does not affect RalB
binding. This implies that helix 1 may contribute more to
RalA interactions than to RalB binding and raises the exciting
prospect that it might be possible to design Ral-isoform-spe-
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cific inhibitors. We also found that the related G protein R-Ras
was able to bind to SP1, albeit with a reduced affinity. The
binding of R-Ras is not surprising when considering the
sequence identity between these two members of the Ras fam-
ily. Of the 14 residues that contact helix2 in the structure (Fig.
3D and Ref. 33) 11 are identical or represent conservative sub-
stitutions in R-Ras. Only Ala-48, Arg-52, and Ser-85 are not
conserved in R-Ras. Ala-48RalB backbone forms a hydrogen
bond with the side chain of Gln-433RLIP76; the replacement of
Ala by Glu in R-Ras should not prevent this directly, although it
may alter the conformation of switch 1. Arg-52RalB forms a
hydrogen bondwith the backbone of the RLIP76 coiled coil and
makes contacts with RLIP76 residues Arg-434, Thr-437, and
Ala-438. Replacement of Arg-52 by the smaller side chain of
Thr in R-Ras would lead to a rearrangement of these interac-
tions. Finally, Ser-85RalB forms a hydrogen bond with Glu-
427RLIP76. This would not be able to form when R-Ras binds to
RLIP76 because it has an Ala at this position. Therefore, the
selectivity of SP1 for Ral proteins over R-Ras probably lies in
just two residues in Ral, Arg-52 and Ser-85. These residues also
both experience chemical shift changes when SP1 binds and
hence contact SP1 directly.
Importantly, SP1 was able to enter mammalian cells, con-
firming its potential for use as a chemical probe and as a starting
point for designing therapeutic peptides. The ability of hydro-
carbon staples to enhance cell penetration is perhaps theirmost
important attribute. Several classes of cell penetration
enhancement sequences have been identified and successfully
employed (52). Enhancement by chemical stapling appears to
be due to an increase in the overall hydrophobicity of the pep-
tide as a result of the chemical clamp and is sequence-indepen-
dent. Cell penetration is likely to be further enhanced by the
overall positive charge carried by SP1, as previous studies have
suggested that positive charge is often favorable for uptake of
constrained peptides into cells (36). A systematic study of
200 peptides showed that charges of1 to7 are optimal
for cellular uptake; as SP1 has a charge of 2, it fits the
profile of a peptide that readily enters cells (53). The same
study showed that the mechanism of cell uptake of stapled
peptides likely involves ATP-dependent endocytosis but is
not dependent on caveolin or clathrin. Rather, it may be
dependent on anionic cell-surface proteoglycans, explaining
the necessity for positive charge.
Our cellular uptake assays indicated that SP1 has a cellular
lifetime of at least 16 h (Fig. 6). Furthermore, the activity assays
were performed 24 h after peptide treatment, demonstrating
that the peptide was effective for a minimum of 24 h. Similar
activity assays using Peptide 1 revealed some activity in cells
after 12 h, but this had fallen back to the control levels by
24 h, presumably due to degradation of the unstapled and,
therefore, unprotected peptide (data not shown). This is
borne out by the lack of signal for FITC-Peptide 1 in cell
penetration assays after 16 h.
Once in cells, SP1 shows clear biological activity.We chose to
use inhibition of nutrient starvation-induced autophagocytosis
as a cellular readout for peptide activity. RalB, but not RalA, is
required for autophagosome biogenesis and is sufficient to acti-
vate autophagy. Thus, autophagosome biogenesis is an iso-
form-specific Ral controlled pathway that gives a clean readout
for inhibition of RalB activity. Our peptides were designed
using the RalB-RLIP76 RBD structure and indeed have a
slightly higher affinity for RalB over RalA. In this assay, clear
inhibition by SP1 was achieved at low micromolar concentra-
tions. We also demonstrated the ability of SP1 to inhibit the
cellular interaction between RalB and its immediate down-
streameffector, Sec5, by inhibition of co-immunoprecipitation.
We expected that SP1 should be able to interfere with multiple
RalB effector interactions due to the overlap of all known bind-
ing sites. RalB activates autophagy via its effector protein,
Exo84. Themechanism of action of RalB in autophagy is known
to be through initiation of vesicle nucleation by assembly of the
ULK1-Beclin1-VPS34 complex directly on Exo84. Thus inhibi-
tion of autophagy suggests that the Exo84 interaction is also
inhibited by SP1 in cells. Taken together, the data demonstrate
that SP1 inhibits RalB-specific pathways via its engineered
mode of action by acting as a pan RalB-effector complex
inhibitor.
The role of autophagy in cancer has been the subject ofmuch
investigation recently. In some contexts autophagy may sup-
press tumorigenesis, but in themajority of situations autophagy
is thought to promote tumorigenesis (54). Autophagy is found
to be up-regulated in Ras-driven cancers, and although this
seems to be context dependent, autophagy inhibitors may well
have utility in defined disease scenarios (55). Thus, the action of
our stapled peptides in a cellular pathway important to Ras-
driven cancers indicates their utility as both a cellular probe and
as a potential therapeutic starting point.
In summary, we have exploited the -helical nature of the
RBD of the Ral effector RLIP76 and rationally designed stabi-
lized -helical peptides that bind to Ral proteins and inhibit
their interactions with downstream effectors. The constrained
peptide displaying the highest affinity for RalB in vitro was also
capable of entering cells and inhibiting RalB-specific cellular
functions. Thus this approach represents a potential strategy to
interferewith Ras andRal signaling aswell as providing a chem-
ical tool to investigate Ral function in vivo. SP1 binds to Ral and
competes with effector proteins, suggesting that it would be
able to switch off Ral signaling completely and, therefore, con-
tribute to the down-regulation of oncogenic Ras. Therapeutics
against Ras-driven cancers are desperately required; this pep-
tide provides an excellent starting point for development of
such a drug that could be used alone or in conjunction with Raf
or PI3K inhibitors in a multipronged attack on aberrant Ras
signaling. These data also provide proof of principle that small
G proteins in their active conformation can be targeted using
this strategy, which has ramifications for many other small G
protein-controlled pathways and, therefore, diseases. Work is
ongoing in our laboratories to improve the affinity of the pep-
tide and further explore in vivo effects.
Experimental Procedures
Peptide Synthesis and Characterization—All peptides were
synthesized using Fmoc-based solid-phase peptide synthesis
(as previously published; Ref. 44) on RinkAmide (MBHA) resin
(30 mol scale). Resin was swollen using 1 ml of N-methyl-2-
pyrrolidone (NMP) for 10 min, then Fmoc-deprotection was
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carried out using 2
 1.5 ml of piperidine (25% v/v) in NMP for
10 min followed by a pair of consecutive dichloromethane and
NMP washes. Standard amino acid couplings were performed
with 800 l of activated amino acid solution consisting of
Fmoc-Xaa-OH (375 l, 0.4 M, 5 eq), PyClock (375 l, 0.4 M, 5
eq), andN,N-diisopropylethylamine (52l, 10 eq). Each residue
was double-coupled at room temperature for 2
 1 h. Unnatu-
ral amino acid solutions contained Fmoc-protected amino acid
(300 l, 0.4 M, 4 eq), PyClock (300 l, 0.4 M, 4 eq), N,N-diiso-
propylethylamine (42 l, 8 equivalents) and were single-cou-
pled for 2 h. Peptides containing unnatural amino acids were
chemically stapled by reaction with 2 
 1 ml of Grubbs’ first
generation catalyst (6 mM) in 1,2-dichloroethane at room tem-
perature for 2 h. After the final Fmoc deprotection, peptide N
termini were acetylated with 2 ml of acetylation solution (4%
acetic anhydride, 16% N,N-diisopropylethylamine in N-meth-
yl-2-pyrrolidone) for 1 h or labeled with FITC with 500 l of
FITC solution (82mg FITC (7 eq), 73l ofN,N-diisopropyleth-
ylamine (14 eq) in dimethylformamide) overnight. Peptide res-
ins were extensively washed with dichloromethane, methanol,
and diethyl ether and dried in a vacuum desiccator overnight
before deprotection using 95% trifluoroacetic acid, 2.5% triiso-
propylsilane, 2.5% water (1.5 ml) for 2.5 h. Peptides were puri-
fied by HPLC and analyzed using LCMS andMALDI. The con-
centrations of stock solutions were checked by amino acid
analysis. See supplemental Table S1 for characterization data
for all peptides synthesized. 6-Carboxyfluorescein peptides
were purchased from Eurogentec.
CircularDichroism Spectroscopy—CD spectrawere recorded
at 1-nm intervals between 190 and 260 nm using a Chirascan
CD spectrometer with a 1-mm path length quartz cuvette.
Three scanswere recorded for each peptide, the datawere aver-
aged, and buffer background was subtracted. Peptides were
measured at 10M in 20mMphosphate buffer, pH 7.5, at 298 K.
The helical content of each peptide was determined using
CDSSTR, Set 7, and DichroWeb (56).
Protein Expression—RalB (residues 1–185, Q72L), RalA
(1–184, Q72L), and RLIP76 RBD (residues 393–446, C411S)
were expressed and purified as described previously (33, 41).
Cultures used to express 15N-labeled RalB were grown in
MOPS minimal media supplemented with 15NH4Cl, as
described previously. All protein tags were cleaved before use,
as previously described (33). Exchange of nucleotide for GMP-
PNP was performed as described previously (49). R-Ras (resi-
dues 23–201, Q89L) was cloned into pET16b (Novagen) and
transformed into BL21(DE3) Escherichia coli. Its expression
was induced by the addition of 1 mM isopropyl 1-thio--D-ga-
lactopyranoside for 3 h, and the protein was purified using an
iminodiacetic acid-Sepharose column (GE Healthcare) and gel
filtration (S75, GE Healthcare).
Isothermal Titration Calorimetry—ITC data were collected
using a MicroCal iTC200 calorimeter at 298 K in 50 mM Tris-
HCl, pH 7.5, 1 mM MgCl2. Peptide (1–2 mM) was titrated into
protein (70 M) in 19 
 2-l additions with 120-s spacing
between injections. Control experiments were performed by
titrating peptides (1–2 mM) into buffer. Data were fitted using
MicroCal Origin 7.0 software using a single-site binding model
(n 1). All data shown are representative of at least two inde-
pendent experiments.
Fluorescence Polarization—Fluorescence polarization exper-
iments were measured on a BMG Labtech Pherastar fluorime-
ter with excitation 485 nm and emission 520 nm at 298 K. Solu-
tionsweremade up in black, flat-bottomed 384-well plates with
30-l total volume per well. Ral proteins were serially diluted
(doubling dilutions) in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl,
and 1 mM MgCl2 (maximum final concentration 50 M) and
added to the plate followed by FITC peptide (final concentra-
tion, 10 nM). Plates were spun at 1000 
 g for 1 min and then
read both immediately and after 30 min of incubation at 298 K.
Data were fitted to a single-site bindingmodel using non-linear
regression analysis in GraphPad Prism 6.0 to obtain Kd values
and their S.E.
Competition fluorescence polarization assays were run as
above using 10 nM FITC-Peptide 5 and 1 M RalBGMPPNP in
the presence of doubling dilutions of Sec5 or RLIP76 Ral bind-
ing domains (maximum final concentration 30 M). Data were
fitted to a sigmoidal dose-response curve using non-linear
regression analysis in GraphPad Prism 6.0 to obtain Kd values
and their S.E.
1H,15N HSQC NMR Spectroscopy—Experiments were
recorded on a Bruker DRX500 at 298 K using 200 M 15N-
labeledRalBGMPPNP in 50mMTris-HCl, pH7.5, 50mMNaCl,
1mMMgCl2, 10%D2O. For the titration experiments, one, two,
five, and eight eq of peptide were added to the protein solution,
and the spectra were recorded after each peptide addition.
NMR data were processed using theAZARA package7 and ana-
lyzed using CCPN ANALYSIS (38). Overall chemical shift per-
turbations, , were calculated using the equation,
 	 1H2 
 0.1515N2 (Eq. 1)
where 1H and 15N are the chemical shift changes for the 1H
and 15N dimensions, respectively.
Cellular Uptake of Peptides—5 
 105 HEK293T cells were
seeded into 35-mm glass-bottom culture dishes and incubated
in 1ml ofDMEMsupplementedwith 10%FBS.After 24 h, FITC
alone, FITC-labeled unstapled Peptide 1, or FITC-labeled sta-
pled peptide SP1 were added to a final concentration of 10 M.
After 16 h the cells were fixed in 4% w/v formaldehyde. Images
were acquired using a Fluoview 300 Laser scanning confocal
microscope with a PLAPON 60
1.42 PLan Apo oil objective
and a 60-m confocal aperture. Cells were excited at 488 nm,
and emitted light was detected at 510–570 nm. All images were
recorded using the same instrument settings.
Co-immunoprecipitation Assays—5 
 106 HEK293T cells
were seeded 48 h before the end point into 10-cm dishes (3 per
condition) in DMEM supplemented with 10% FBS. The
medium was aspirated, and fresh DMEM (with 10% FBS) with
and without 6-carboxyfluorescein (FAM)-SP1 or -SP6 (at 100
Meach)was added 24 h before the end point. Themediumwas
then replaced with 1
 EBSS (Earle’s balanced salt solution) 90
min before the end point. At the end point, cells were lysed in
lysis buffer (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 1% Triton
7 W. Boucher, unpublished data.
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X-100, 0.5% sodium deoxycholate, 10% glycerol, 10 mMMgCl2,
2mMEGTA, 1mMPMSF, 50mMNaF, 1mMNaVO4, and 80mM
-glycerophosphate plus EDTA-free protease inhibitor mix-
ture (Roche Applied Science 04693159001)). After 15 min lysis
at 4 °C, lysates were cleared at 20,000
 g for 20min at 4 °C. Cell
lysates were diluted with lysis buffer to prepare 120 l of whole
cell lysate (4 g/l) and 1400 l of immunoprecipitation lysate
(6 g/l) for each condition. Endogenous RalB was immuno-
precipitated by the addition of 30 l of mouse anti-RalB anti-
body (a kind gift from Larry Feig, Tufts University) to immuno-
precipitation lysates at 4 °C for 4 h. Protein A/G-agarose beads
(Santa Cruz Biotechnology Inc., sc-2003) were added for 1 h at
4 °C to precipitate antibody-antigen complexes. Precipitated
complexes were washed 3 times with lysis buffer for 5 min at
4 °C. The samples were then separated via SDS-PAGE and
transferred to PVDF membranes (Immobilon-P). Membranes
were probed by immunoblotting with the following primary
antibodies: rabbit anti-RalB (Cell Signaling Technology
cs-3523, lot 1) and mouse anti-Sec5 (a kind gift from Charles
Yeaman, University of Iowa).
GFP-LC3 Fluorescence Quantification and Imaging—72 h
before the end point, 8
 103 HeLa cells stably expressing GPF-
LC3were plated perwell of glass-bottomed 96-well plates. Cells
were plated in 100 ml of DMEM supplemented with 10% FBS
and grown for 48 h. 24 h before the end point, the medium was
changed with 100 ml of fresh DMEM (with 10% FBS). DMSO
and peptides were added 24 h before the end point at the final
indicated concentrations (final concentration of DMSO per
well was 1%). 4 h before the end point, cells were washed twice
with PBS (withCa2 andMg2) and then fedwith either 100ml
of 1
 (EBSS) or serum-free DMEM as indicated. At the end
point, EBSS-treated cells were washed once, and serum-free
DMEM-treated cells were washed twice with 1
 PBS (with
Ca2 andMg2). Cells were then fixed in 4% paraformaldehyde
in 1
 PBS (with Ca2 and Mg2) for 10 min. Cells were then
washed twice as before and then stained with 0.01%Hoechst in
1
 PBS (with Ca2 and Mg2) for 20 min. Total fluorescence
intensity for GFP and Hoechst was measured using the
PheraStar FS plate-reader. For epifluorescence imaging, HeLa
cells stably expressing GPF-LC3 were grown in 384-well plates
in DMEM (with 10% FBS) for 48 h. The medium was not
changed for DMEM-treated cells, and EBSS-treated cells were
starved for 2 h before live-cell imaging at 20
 via the (BD Bio-
sciences) Pathway 855 High-Content Bioimager.
GFP-TFEB Activation—5 
 103 HeLa cells stably expressing
GFP-TFEB (48) were plated in 500 l of DMEM (with 10% FBS)
perwell of8-ChamberLab-Tek IIChambered#1.5GermanCov-
erglass slides and grown overnight. 24 h before imaging, the
mediumwas changedwith 265l of freshDMEM(with 10%FBS)
andDMSOor peptides at the final concentrations indicated (final
concentration of DMSOperwell was 1%). 24 h after peptide addi-
tion, live-cell images were acquired with an Andor Spinning Disc
Confocal Microscope (oil immersion and 60
 objective) under
normal cell culture conditions (37 °C, 5% CO2). Initial images of
fed-state cellswere taken 24h after peptide addition.Themedium
in each well was then changed with 265 l of 1
 EBSS, and sub-
sequent images were taken at the times indicated.
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